224 related articles for article (PubMed ID: 20665105)
1. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
Prieto-Alhambra D; Javaid MK; Servitja S; Arden NK; Martinez-García M; Diez-Perez A; Albanell J; Tusquets I; Nogues X
Breast Cancer Res Treat; 2011 Feb; 125(3):869-78. PubMed ID: 20665105
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
3. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
[TBL] [Abstract][Full Text] [Related]
4. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
Servitja S; Nogués X; Prieto-Alhambra D; Martínez-García M; Garrigós L; Peña MJ; de Ramon M; Díez-Pérez A; Albanell J; Tusquets I
Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.
Prieto-Alhambra D; Servitja S; Javaid MK; Garrigós L; Arden NK; Cooper C; Albanell J; Tusquets I; Diez-Perez A; Nogues X
Breast Cancer Res Treat; 2012 Jun; 133(3):1159-67. PubMed ID: 22434523
[TBL] [Abstract][Full Text] [Related]
6. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Singh S; Cuzick J; Mesher D; Richmond B; Howell A
Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
[TBL] [Abstract][Full Text] [Related]
7. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
[TBL] [Abstract][Full Text] [Related]
8. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
Garcia-Giralt N; Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Torres-Del Pliego E; Balcells S; Albanell J; Grinberg D; Diez-Perez A; Tusquets I; Nogués X
Breast Cancer Res Treat; 2013 Jul; 140(2):385-95. PubMed ID: 23868189
[TBL] [Abstract][Full Text] [Related]
11. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Niravath P; Chen B; Chapman JW; Agarwal SK; Welschhans RL; Bongartz T; Kalari KR; Shepherd LE; Bartlett J; Pritchard K; Gelmon K; Hilsenbeck SG; Rimawi MF; Osborne CK; Goss PE; Ingle JN
Clin Breast Cancer; 2018 Feb; 18(1):78-87. PubMed ID: 29128193
[TBL] [Abstract][Full Text] [Related]
14. Joint pain and falls among women with breast cancer on aromatase inhibitors.
Basal C; Vertosick E; Gillis TA; Li Q; Bao T; Vickers A; Mao JJ
Support Care Cancer; 2019 Jun; 27(6):2195-2202. PubMed ID: 30306326
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Niravath P; Hilsenbeck SG; Wang T; Jiralerspong S; Nangia J; Pavlick A; Ademuyiwa F; Frith A; Ma C; Park H; Rigden C; Suresh R; Ellis M; Kent Osborne C; Rimawi MF
Breast Cancer Res Treat; 2019 Sep; 177(2):427-435. PubMed ID: 31218477
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
Karaplis AC; Chouha F; Djandji M; Sampalis JS; Hanley DA
Ann Pharmacother; 2011 May; 45(5):561-8. PubMed ID: 21521859
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.
Nyrop KA; Muss HB; Hackney B; Cleveland R; Altpeter M; Callahan LF
J Geriatr Oncol; 2014 Apr; 5(2):148-55. PubMed ID: 24495696
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
20. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]